LOADING

Type to search

Early DMD Data Not as Robust For Solid Biosciences as Investors Hoped

BioTech

Early DMD Data Not as Robust For Solid Biosciences as Investors Hoped

Share
early-dmd-data-not-as-robust-for-solid-biosciences-as-investors-hoped

Shares of Solid Biosciences have plunged more than 71 percent after the company revealed early data from a Phase I/II trial that showed low doses of its gene therapy treatment may lack the potential to be as effective a treatment for Duchenne muscular dystrophy as current products on the market.

Leave a Comment

Your email address will not be published. Required fields are marked *